At a glance
- Originator Aventis Japan
- Class Antibacterials; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 24 Dec 1999 Hoechst has merged with Rhône-Poulenc to form Aventis
- 20 Feb 1998 New profile
- 20 Feb 1998 Preclinical development for Staphylococcal infections in Japan (Unknown route)